Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in POTS
NCT03261570 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 51
Last updated 2022-09-28
Summary
Postural tachycardia syndrome (POTS), is the chronic form of orthostatic intolerance associated with excessive upright tachycardia, and occurs predominantly in young females (\>85%). Among its most troubling symptoms are lightheadedness, fatigue, and decreased memory often called "brain fog" by patients. Task-related neurovascular coupling (NVC) links neural activity to an increase in CBF known as "functional hyperemia". Although memory task performance and NVC deteriorated with angle of tilt in POTS but not healthy controls, cerebral blood flow (CBF) remained similar to control. Instead, the investigators observed extensive narrow band low frequency (0.07-0.13 Hz) oscillations in BP (OBP) that entrained and amplified oscillations in CBF (OCBF). OBP and OCBF increased with tilt angle and caused impaired working memory and reduced functional hyperemia. The cardiovagal baroreflex couples BP to HR to buffer BP changes. The investigators hypothesize that the cardiovagal baroreflex becomes progressively impaired with orthostasis in POTS, but not in healthy volunteers, and accounts for OBP, OCBF, and loss of NVC; further, improving the baroreflex reduces OBP, OCBF and Brain Fog in POTS.
Conditions
- Postural Orthostatic Tachycardia Syndrome (POTS)
- POTS
- Orthostatic Intolerance
Interventions
- DRUG
-
Pyridostigmine
60mg by mouth
- DRUG
-
Digoxin
0.5 (500mcg) by mouth
- DRUG
-
Lactulose 50mg by mouth
Sponsors & Collaborators
-
National Institutes of Health (NIH)
collaborator NIH -
New York Medical College
lead OTHER
Principal Investigators
-
Julian M. Stewart, M.D., Ph.D. · New York Medical College
Study Design
- Allocation
- RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- QUADRUPLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 15 Years
- Max Age
- 30 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2017-07-01
- Primary Completion
- 2022-06-01
- Completion
- 2022-06-01
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Local Vasoconstriction in Postural Tachycardia Syndrome
NCT01210430 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome
NCT03182725 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)
NCT06593600 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Using Mirabegron to Increase BP in Patients With POTS
NCT06133075 ·Status: COMPLETED ·Phase: PHASE2
-
Crossover Study of Propranolol vs Ivabradine in POTS
NCT04186286 ·Status: RECRUITING ·Phase: PHASE2
-
Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist
NCT03070730 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Intravenous (IV) Saline and Exercise in Postural Tachycardia Syndrome (POTS)
NCT01000350 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Safety Study of Pyridostigmine in Heart Failure
NCT01415921 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Autonomic Disorders: A Training Protocol
NCT02154009 ·Status: TERMINATED
-
POTS Adrenergic Ab (CIHR Aims #1&2)
NCT02673996 ·Status: RECRUITING
-
POTS NET mRNA Functional Correlation With NET Activity
NCT03218761 ·Status: ACTIVE_NOT_RECRUITING
-
Cardiovascular Effects of Selective I(f)-Channel Blockade
NCT00865917 ·Status: UNKNOWN ·Phase: PHASE2
-
Effect of Exercise in OI
NCT00770484 ·Status: COMPLETED ·Phase: NA
-
Anxiety and Vagal Control of the Heart in Coronary Disease
NCT00006311 ·Status: COMPLETED
-
Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study
NCT02308124 ·Status: COMPLETED ·Phase: PHASE4
-
Non-Pharmacologic Therapy for Neurocardiogenic Syncope
NCT00096902 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Trial for the Prevention of Vasovagal Syncope
NCT00118482 ·Status: COMPLETED ·Phase: PHASE4
-
The Pathophysiology of Orthostatic Hypotension
NCT00748059 ·Status: COMPLETED ·Phase: PHASE1
-
A Study in Subjects With Neurogenic Orthostatic Hypotension
NCT07089043 ·Status: RECRUITING ·Phase: PHASE2
-
The Effect of Ivabradine on Patients With Postural Tachycardia Syndrome
NCT01761825 ·Status: UNKNOWN ·Phase: PHASE2
-
A Dose Response Trial Using 5 and 10 Mg of Midodrine Hydrochloride
NCT00426842 ·Status: COMPLETED ·Phase: PHASE2
-
Intravenous Norepinephrine for Orthostatic Hypotension
NCT01285908 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Hyporeactivity and Gulf War Illness
NCT00100412 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Tolerance of Flucortac in Patients With Orthostatic Neurogenic Hypotension
NCT04128137 ·Status: UNKNOWN ·Phase: PHASE4
-
Hypnosis in Autonomic Function
NCT00061009 ·Status: COMPLETED